How Much Economic Value Do Health Interventions Really Deliver?

Building a Health‑Economics Framework

The February 2026 McKinsey report "The health of nations: Stronger health, stronger economies" leverages the IHME GBD 2021 database to construct a Prioritizing Health model that links health improvements to economic outcomes. The model follows three steps: estimating health gains from interventions, quantifying the economic benefits of those gains, and calculating incremental costs and returns of health investments.

Scope of Disease and Risk Coverage

The analysis covers 89 diseases—representing 85% of the global disease burden—and 27 health‑risk factors, accounting for about 98% of risk‑attributed disease burden, ensuring comprehensive coverage.

Identifying Scalable, Cost‑Effective Interventions

Drawing on WHO guidelines, Cochrane reviews, and The Lancet, the report selects roughly 300 interventions that are both cost‑effective and scalable. These are grouped into three categories: population‑environment interventions, individual preventive measures, and clinical treatment interventions. A nine‑step analytical method estimates the health impact of each intervention, with adoption targets tailored to country income levels (e.g., 100% for policy‑level measures, 95% for vaccines, 90% for routine clinical care).

Six Channels Translating Health Gains into Economic Growth

Prevent premature death to expand labor supply.

Reduce disease‑related disability to lower absenteeism.

Free informal caregivers to join the formal labor market.

Improve health of employed workers to boost productivity.

Enhance child and adolescent health to secure future earnings potential.

Increase efficiency of employed caregivers.

For example, effective interventions for depression and anxiety can raise productivity by 5% by eliminating presenteeism losses.

Quantifying Investment Returns

The report uses the disability‑adjusted life year (DALY) averted cost as the core metric, applying a six‑step process to estimate full‑scale cost‑benefit data for about 60,000 country‑intervention combinations. Cost scaling factors are set by income group (LIC = 1.0, LMIC = 1.4, UMIC = 4.1, HIC = 7.6). An intervention is deemed high‑value when its cost per DALY averted is less than three times the country's per‑capita GDP, aligning with WHO cost‑effectiveness thresholds.

Conclusion

Investing in national health is a strategic long‑term economic driver, enhancing lifespan, quality of life, and human‑capital productivity. Policymakers and market participants should focus not on whether to invest in health, but on selecting high‑value, scalable interventions that convert health gains into sustained economic growth.